Advertisement

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement

Dec

11

Today In Oncology

Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer

Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy-Refractory Advanced Breast Cancers

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers

Oral SERD Improves Disease-Free Survival Over Standard of Care for Patients With Early-Stage Breast Cancer

Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer

Advertisement

© 2025 HSP News Service, L.L.C.